Acumen Pharmaceuticals (ABOS) Current Assets (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Current Assets data on file, last reported at $133.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 14.1% year-over-year to $133.1 million; the trailing twelve-month figure through Mar 2026 stood at $133.1 million (down 14.1% YoY), and the FY2025 full-year result was $122.3 million, down 31.44% from the prior year.
• Current Assets climbed to $133.1 million in Q1 2026, from $122.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $266.9 million in Q2 2024 to a low of $122.3 million in Q4 2025.
• A 5-year average of $183.8 million and a median of $180.3 million in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 170.72% in 2022 and plunged 44.4% in 2025, its largest moves.
• Tracing ABOS's Current Assets over 5 years: stood at $180.3 million in 2022, then surged by 36.76% to $246.6 million in 2023, then fell by 27.7% to $178.3 million in 2024, then slumped by 31.44% to $122.3 million in 2025, then grew by 8.87% to $133.1 million in 2026.
• Business Quant data shows ABOS's Current Assets at $133.1 million in Q1 2026, $122.3 million in Q4 2025, and $132.2 million in Q3 2025.